Background: Estimation of Estrogen Receptor (ER) Progesterone Receptor (PR) and Human Epidermal Growth Factor Receptor 2 (HER2) is mandatory for choosing treatment options and prognosis of breast cancer patients. This estimation can be done by Immunohistochemistry (IHC) and Fluoroscence In Situ Hybridization (FISH) test. As the tests are expensive many of our patients can't afford to do it. But if we practice doing the test routinely the cost will be reduced and our patients will be benefited. So we underwent a primitive study on receptor status in breast cancer patients. Our goal was to encourage the surgeons to advice receptor status routinely and treat the patients accordingly as patients prognosis will be much more better if they are treated according to their receptor status. Methods: This was a retrospective observational study of 74 breast cancer patients in a private clinic. In this study we have shown their receptor status by IHC and the data were analyzed. Results: Among the 74 patients 32 were ER +ve PR +ve, 11 were ER +ve PR -ve, 02 were ER -ve PR +ve, 29 were ER -ve PR -ve. ER &/or PR positive patients will be more responsive to hormone therapy. 28 patients were HER2 +ve, 34 patients were HER2 -ve and 9 were equivocal. HER2 positive patients will be benefited from targeted therapy. Among the patients 11 were triple negative that means they have worst prognosis. Conclusion: As knowing the receptor status in breast cancer help us as a predictive, prognostic and therapeutic indicator, we must advice it routinely and take steps to make it cheaper and easily available.
INTRODUCTION
Incidence of breast cancer is increasing day by day. Breast carcinoma is a heterogeneous disease with a wide spectrum of clinical, pathologic and molecular features 1 . Breast cancer is not only a heterogenous disease but also a hormone dependent disease 2 
RESULTS
Out of 80 patients 74 breast cancer patients could afford immunohistochemistry for knowing their receptor status. HER2 was not done in three patients. Among the 74 patient 11 were triple negative that is ER, PR and HER2 negative, which means they have the worst prognosis, worst overall and disease-free survival.
DISCUSSIONS
Biomarkers can be prognostic, predictive or both. Biomarkers testing which should be done are ER, PR, HER2, Ki67 and CK5. Due to unavailability we couldn't do Ki67 and Ck5. ER, PR is a weak prognostic but strong predictive biomarker. If ER, PR positive (As in 70% invasive cancer) we can predict that patient will likely be benefited from endocrine therapy like tamoxifen. The overexpression of oncogene HER2 (in 15-20% invasive cancer) is both a prognostic and predictive biomarker. It is done by immunohistochemistry or FISH method. Positive HER2 is associated with bad prognosis ie. higher risk of recurrence and mortality. It also predicts that patient will more likely benefit from targeted therapy. HER2 is a negative prognostic factor and is associated with shorter disease free and overall survival.
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